Epidemiology and management of hyperlipidemia.
Karr S.
Am J Manag Care. 2017 Jun;23(9 Suppl):S139-S148.
Familial combined hyperlipidemia is a polygenic trait.
Gill PK, Hegele RA.
Curr Opin Lipidol. 2022 Apr 1;33(2):126-132. doi: 10.1097/MOL.0000000000000796.
Hyperlipidemia.
Stewart J, McCallin T, Martinez J, Chacko S, Yusuf S.
Pediatr Rev. 2020 Aug;41(8):393-402. doi: 10.1542/pir.2019-0053.
Genetics of Familial Combined Hyperlipidemia (FCHL) Disorder: An Update.
Taghizadeh E, Farahani N, Mardani R, Taheri F, Taghizadeh H, Gheibihayat SM.
Biochem Genet. 2022 Apr;60(2):453-481. doi: 10.1007/s10528-021-10130-2. Epub 2021 Sep 3.
New Therapies for Primary Hyperlipidemia.
Aguilar-Salinas CA, Gómez-Díaz RA, Corral P.
J Clin Endocrinol Metab. 2022 Apr 19;107(5):1216-1224. doi: 10.1210/clinem/dgab876.
Mechanisms underlying direct actions of hyperlipidemia on myocardium: an updated review.
Yao YS, Li TD, Zeng ZH.
Lipids Health Dis. 2020 Feb 8;19(1):23. doi: 10.1186/s12944-019-1171-8.
Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments.
Yanai H, Adachi H, Hakoshima M, Katsuyama H.
Int J Mol Sci. 2023 Sep 11;24(18):13942. doi: 10.3390/ijms241813942.
Lipoprotein(a) and familial hypercholesterolemia: Partners in crime in heritable hyperlipidemia.
Kamstrup PR.
Atherosclerosis. 2023 Jan;365:25-26. doi: 10.1016/j.atherosclerosis.2022.12.009. Epub 2022 Dec 24.
Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis.
Tummala R, Gupta M, Devanabanda AR, Bandyopadhyay D, Aronow WS, Ray KK, Mamas M, Ghosh RK.
Ann Med. 2022 Dec;54(1):1287-1296. doi: 10.1080/07853890.2022.2059559.
Hypertriglyceridaemia: an update.
Wierzbicki AS, Kim EJ, Esan O, Ramachandran R.
J Clin Pathol. 2022 Dec;75(12):798-806. doi: 10.1136/jclinpath-2021-207719. Epub 2022 Jun 16.
